about
Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in ZanzibarEfficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trialAntimalarial exposure delays Plasmodium falciparum intra-erythrocytic cycle and drives drug transporter genes expressionInfluence of rapid malaria diagnostic tests on treatment and health outcome in fever patients, Zanzibar: a crossover validation studyNovel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistanceLoop-mediated isothermal amplification (LAMP) for point-of-care detection of asymptomatic low-density malaria parasite carriers in ZanzibarIdentification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient dataBaseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis.Spatial Distribution of Falciparum Malaria Infections in Zanzibar: Implications for Focal Drug Administration Strategies Targeting Asymptomatic Parasite Carriers.Malaria rapid testing by community health workers is effective and safe for targeting malaria treatment: randomised cross-over trial in TanzaniaPharmacodynamic interactions among atovaquone, proguanil and cycloguanil against Plasmodium falciparum in vitro.Loop mediated isothermal amplification (LAMP) accurately detects malaria DNA from filter paper blood samples of low density parasitaemiasSystem effectiveness of a targeted free mass distribution of long lasting insecticidal nets in Zanzibar, TanzaniaPolymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania.A qualitative study on caretakers' perceived need of bed-nets after reduced malaria transmission in Zanzibar, TanzaniaReductions in malaria and anaemia case and death burden at hospitals following scale-up of malaria control in Zanzibar, 1999-2008Epidemiology of malaria in a village in the Rufiji River Delta, Tanzania: declining transmission over 25 years revealed by different parasitological metrics.Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial.The usefulness of rapid diagnostic tests in the new context of low malaria transmission in ZanzibarMalaria associated anaemia, drug resistance and antimalarial combination therapy.SYBR Green real-time PCR-RFLP assay targeting the plasmodium cytochrome B gene--a highly sensitive molecular tool for malaria parasite detection and species determination.Polymorphisms in the K13-propeller gene in artemisinin-susceptible Plasmodium falciparum parasites from Bougoula-Hameau and Bandiagara, MaliField deployment of loop-mediated isothermal amplification for centralized mass-screening of asymptomatic malaria in Zanzibar: a pre-elimination setting.Independent evolution of pyrimethamine resistance in Plasmodium falciparum isolates in Melanesia.Drug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America.Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria.Acute Uncomplicated Febrile Illness in Children Aged 2-59 months in Zanzibar - Aetiologies, Antibiotic Treatment and Outcome.Public health impact of drug resistant Plasmodium falciparum malaria.MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy.Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial.Quinine treatment selects the pfnhe-1 ms4760-1 polymorphism in Malian patients with Falciparum malariaAssessing the cost-benefit effect of a Plasmodium falciparum drug resistance mutation on parasite growth in vitro.A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections.Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphismsHigh effective coverage of vector control interventions in children after achieving low malaria transmission in Zanzibar, TanzaniaPrevalence of PCR detectable malaria infection among febrile patients with a negative Plasmodium falciparum specific rapid diagnostic test in Zanzibar.Little Polymorphism at the K13 Propeller Locus in Worldwide Plasmodium falciparum Populations Prior to the Introduction of Artemisinin Combination Therapies.Impact of training in clinical and microscopy diagnosis of childhood malaria on antimalarial drug prescription and health outcome at primary health care level in Tanzania: a randomized controlled trial
P50
Q22061782-B8EDCDBE-E82C-4197-8EA8-ADB251D8F2DAQ28297711-655E2F3D-CA02-4508-817E-FF71A16DF31EQ28475290-11EE58F6-898B-42E6-8E17-3C77489FAC81Q28475325-9786178E-532B-4D76-8E3E-CE5EA1C671B4Q28478286-45D48FC0-5CDE-4410-B2B7-2FA8DAF3758EQ28650434-BB11CD1B-840C-402C-8380-A40F6C917933Q30818645-3DF9B5B0-F2E3-4DB5-96CC-AAA023BEFDA5Q30936416-AF320EE3-F826-4695-B3F9-E904408B9C41Q30995133-7EEA0713-3B5B-4954-AFB3-626BA46F9754Q33589268-07C905B7-A6AE-48B0-A676-8CE35B93CBD6Q33959247-214D07E2-35FF-4896-B410-57F42FDA3376Q33979471-A45F8F2C-C837-4513-8F5C-CE4CF2680658Q34020320-46FA82CA-6159-4459-B6D3-C769BD0B4122Q34025931-1C155480-0410-4F81-8B83-2767C39B1651Q34281680-200B6B5A-5729-4AAF-83B7-AB037E78E7F6Q34290067-487F1BF1-A6B6-44D4-A82F-501E80970E11Q34366064-18486C9A-F7FB-4160-9FA4-FFE02699682DQ34633263-D2202759-8A71-4D9E-AF55-62592145FDB4Q34898273-74A6820F-618F-4922-81F1-8D504965EF66Q34910448-C1FF3C01-AB7D-4247-BDCF-5056BEB80C05Q34984133-EDDDD471-734F-493B-8FE0-7C59153119BEQ34999477-BA3C6311-7FDF-4D8C-8530-B35838B96E2BQ35182256-B3780F5F-541C-4897-AC79-D9FCEBE3B365Q35616221-4E16BDD0-F39D-43A0-A292-2E500EFFF421Q35633732-BE2E3F30-06CA-489D-ADCD-8368F24AB896Q35647764-AE236AC8-E6C0-4A50-BAC8-DC3ABC51EC2CQ35698213-D1A0FBAC-5B90-4378-8623-EBE85E35E286Q35761064-9B419DB7-4F95-4A96-96B7-E5D43801A955Q35907325-D003C9A6-2AD9-4B22-A0D2-FD7C0895D346Q36127197-E8B85D89-7693-4447-9FCE-F57C4FA36650Q36412071-7CD31C4F-4C19-460D-BFAF-178673A512EEQ36501878-F375255B-B3D6-40FB-A946-60C9809E0233Q36509807-3DC31DB1-20C0-4D10-B08A-71E4B61F7AC4Q36558529-A52FE502-77A4-4113-BDC2-02B4DF162D1BQ36579251-C98BF83C-222A-4B48-8A4F-416E09692EDBQ36584636-E8E1CE4F-7E61-4DB2-83B2-E0B769D82816Q36588381-A15615FA-4E54-4F80-907D-FEF7495CEF90Q36641781-E7E589DF-4DF0-464E-A804-D69AC817617CQ36933412-076F0315-D372-4D4C-9CD2-A9ECC0983E56Q36934748-D33F893F-21B1-49DF-94E3-2B6012BD7CE1
P50
description
Swedish professor of Infectious Diseases
@en
Zweeds onderzoeker
@nl
svensk professor i infektionssjukdomar
@sv
name
Anders Björkman
@da
Anders Björkman
@de
Anders Björkman
@en
Anders Björkman
@es
Anders Björkman
@nl
Anders Björkman
@no
Anders Björkman
@sl
Anders Björkman
@sv
type
label
Anders Björkman
@da
Anders Björkman
@de
Anders Björkman
@en
Anders Björkman
@es
Anders Björkman
@nl
Anders Björkman
@no
Anders Björkman
@sl
Anders Björkman
@sv
altLabel
Anders Bjorkman
@en
prefLabel
Anders Björkman
@da
Anders Björkman
@de
Anders Björkman
@en
Anders Björkman
@es
Anders Björkman
@nl
Anders Björkman
@no
Anders Björkman
@sl
Anders Björkman
@sv
P214
P106
P21
P213
0000 0001 3813 8329